These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6546732)

  • 21. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer.
    Hempling RE; Piver MS; Natarajan N; Baker TR; Thompson JM; Hicks ML; Mettlin CJ
    J Surg Oncol; 1993 Sep; 54(1):38-44. PubMed ID: 8377503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study.
    Creasman WT; Omura GA; Brady MF; Yordan E; DiSaia PJ; Beecham J
    Gynecol Oncol; 1990 Dec; 39(3):239-43. PubMed ID: 2258063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
    Smith MR; Peters WA; Drescher CW
    Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of the 1st Austrian ovarian cancer study: prospective randomized comparison of a new sequential chemotherapy with 2 standard regimens in 150 stage III and IV patients].
    Sevelda P; Salzer H; Gitsch E; Karrer K
    Onkologie; 1985 Dec; 8(6):388-91. PubMed ID: 3912695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
    Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined modality treatment for stage III ovarian carcinoma.
    Rizel S; Biran S; Anteby SO; Brufman G; Sulkes A; Milwidsky A; Weshler Z; Fuks Z
    Radiother Oncol; 1985 Apr; 3(3):237-44. PubMed ID: 2988025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
    Baker TR; Piver MS; Hempling RE
    Cancer; 1994 Jul; 74(2):656-63. PubMed ID: 8033045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].
    Kühnle H; Hilfrich J
    Onkologie; 1985 Dec; 8(6):374-82. PubMed ID: 3912694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
    Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
    Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian carcinoma: results of radiation therapy and chemotherapy in 83 patients.
    Shehata WM; Meyer RL; Cormier WJ; Jazy FK
    Radiology; 1987 May; 163(2):539-43. PubMed ID: 3562839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of 63 advanced ovarian carcinomas].
    Liu LY; Hong WJ; Hou YJ; Yao ZH; Wu AR; Li L
    Zhonghua Zhong Liu Za Zhi; 1987 Sep; 9(5):375-8. PubMed ID: 3452529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic factors of common epithelial ovarian cancer treated by surgery and cisplatin based combination chemotherapy].
    Sasaki H; Ochiai K; Terashima Y; Mochizuki S; Soda T; Nishimura H; Yakushiji M; Hirabayashi M
    Gan No Rinsho; 1989 Oct; 35(13):1615-20. PubMed ID: 2585733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapeutic management of ovarian cancer.
    Dembo AJ
    Semin Oncol; 1984 Sep; 11(3):238-50. PubMed ID: 6435249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.